Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal

G.W. Canonica; F. Blasi; P. Paggiaro; G. Senna; G. Passalacqua; A. Spanevello; S. Aliberti; D. Bagnasco; M. Bonavia; M. Bonini; L. Brussino; C. Bucca; M.F. Caiaffa; C. Calabrese; G. Camiciottoli; M. Caminati; G.E. Carpagnano; C. Caruso; S. Centanni; M.E. Conte; A.G. Corsico; L. Cosmi; M.T. Costantino; N. Crimi; S. D'Alò; M. D'Amato; S. Del Giacco; A. Farsi; E. Favero; M.P. Foschino Barbaro; G. Guarnieri; G. Guida; M. Latorre; S. Lo Cicero; C. Lombardi; L. Macchia; F. Mazza; F. Menzella; M. Milanese; M. Montagni; P. Montuschi; E. Nucera; R. Parente; V. Patella; G. Pelaia; L. Pini; F. Puggioni; L. Ricciardi; F.L.M. Ricciardolo; L. Richeldi; E. Ridolo; G. Rolla; P. Santus; N. Scichilone; G. Spadaro; A. Vianello; V. Viviano; M.R. Yacoub; M.C. Zappa; E. Heffler; SANI (Severe Asthma Network Italy)

doi:10.1016/j.waojou.2020.100464

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal

G.W. Canonica, F. Blasi, P. Paggiaro, G. Senna, G. Passalacqua, A. Spanevello, S. Aliberti, D. Bagnasco, M. Bonavia, M. Bonini, L. Brussino, C. Bucca, M.F. Caiaffa, C. Calabrese, G. Camiciottoli, M. Caminati, G.E. Carpagnano, C. Caruso, S. Centanni, M.E. ConteA.G. Corsico, L. Cosmi, M.T. Costantino, N. Crimi, S. D'Alò, M. D'Amato, S. Del Giacco, A. Farsi, E. Favero, M.P. Foschino Barbaro, G. Guarnieri, G. Guida, M. Latorre, S. Lo Cicero, C. Lombardi, L. Macchia, F. Mazza, F. Menzella, M. Milanese, M. Montagni, P. Montuschi, E. Nucera, R. Parente, V. Patella, G. Pelaia, L. Pini, F. Puggioni, L. Ricciardi, F.L.M. Ricciardolo, L. Richeldi, E. Ridolo, G. Rolla, P. Santus, N. Scichilone, G. Spadaro, A. Vianello, V. Viviano, M.R. Yacoub, M.C. Zappa, E. Heffler, SANI (Severe Asthma Network Italy)

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics. © 2020 The Authors

Original language	English
Journal	World Allergy Organ. J.
Volume	13
Issue number	10
DOIs	https://doi.org/10.1016/j.waojou.2020.100464
Publication status	Published - 2020

Keywords

Biologics
Oral corticosteroids
Real-life
Registr
Severe asthma
benralizumab
biological product
corticosteroid
dupilumab
mepolizumab
omalizumab
asthma
clinical outcome
disease exacerbation
disease registry
drug effect
forced expiratory volume
human
Italy
medication overuse
priority journal
quality of life
Review

Access to Document

10.1016/j.waojou.2020.100464

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091219259&doi=10.1016%2fj.waojou.2020.100464&partnerID=40&md5=ed8165eca34dcc53d11dcbfebb6f8783

Cite this

Canonica, G. W., Blasi, F., Paggiaro, P., Senna, G., Passalacqua, G., Spanevello, A., Aliberti, S., Bagnasco, D., Bonavia, M., Bonini, M., Brussino, L., Bucca, C., Caiaffa, M. F., Calabrese, C., Camiciottoli, G., Caminati, M., Carpagnano, G. E., Caruso, C., Centanni, S., ... Italy), SANI. (2020). Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal. World Allergy Organ. J., 13(10). https://doi.org/10.1016/j.waojou.2020.100464

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) : World Allergy Organization Journal. / Canonica, G.W.; Blasi, F.; Paggiaro, P.; Senna, G.; Passalacqua, G.; Spanevello, A.; Aliberti, S.; Bagnasco, D.; Bonavia, M.; Bonini, M.; Brussino, L.; Bucca, C.; Caiaffa, M.F.; Calabrese, C.; Camiciottoli, G.; Caminati, M.; Carpagnano, G.E.; Caruso, C.; Centanni, S.; Conte, M.E.; Corsico, A.G.; Cosmi, L.; Costantino, M.T.; Crimi, N.; D'Alò, S.; D'Amato, M.; Del Giacco, S.; Farsi, A.; Favero, E.; Foschino Barbaro, M.P.; Guarnieri, G.; Guida, G.; Latorre, M.; Lo Cicero, S.; Lombardi, C.; Macchia, L.; Mazza, F.; Menzella, F.; Milanese, M.; Montagni, M.; Montuschi, P.; Nucera, E.; Parente, R.; Patella, V.; Pelaia, G.; Pini, L.; Puggioni, F.; Ricciardi, L.; Ricciardolo, F.L.M.; Richeldi, L.; Ridolo, E.; Rolla, G.; Santus, P.; Scichilone, N.; Spadaro, G.; Vianello, A.; Viviano, V.; Yacoub, M.R.; Zappa, M.C.; Heffler, E.; Italy), SANI (Severe Asthma Network.

In: World Allergy Organ. J., Vol. 13, No. 10, 2020.

Research output: Contribution to journal › Article › peer-review

Canonica, GW, Blasi, F, Paggiaro, P, Senna, G, Passalacqua, G, Spanevello, A, Aliberti, S, Bagnasco, D, Bonavia, M, Bonini, M, Brussino, L, Bucca, C, Caiaffa, MF, Calabrese, C, Camiciottoli, G, Caminati, M, Carpagnano, GE, Caruso, C, Centanni, S, Conte, ME, Corsico, AG, Cosmi, L, Costantino, MT, Crimi, N, D'Alò, S, D'Amato, M, Del Giacco, S, Farsi, A, Favero, E, Foschino Barbaro, MP, Guarnieri, G, Guida, G, Latorre, M, Lo Cicero, S, Lombardi, C, Macchia, L, Mazza, F, Menzella, F, Milanese, M, Montagni, M, Montuschi, P, Nucera, E, Parente, R, Patella, V, Pelaia, G, Pini, L, Puggioni, F, Ricciardi, L, Ricciardolo, FLM, Richeldi, L, Ridolo, E, Rolla, G, Santus, P, Scichilone, N, Spadaro, G, Vianello, A, Viviano, V, Yacoub, MR, Zappa, MC, Heffler, E & Italy), SANI 2020, 'Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal', World Allergy Organ. J., vol. 13, no. 10. https://doi.org/10.1016/j.waojou.2020.100464

Canonica, G.W. ; Blasi, F. ; Paggiaro, P. ; Senna, G. ; Passalacqua, G. ; Spanevello, A. ; Aliberti, S. ; Bagnasco, D. ; Bonavia, M. ; Bonini, M. ; Brussino, L. ; Bucca, C. ; Caiaffa, M.F. ; Calabrese, C. ; Camiciottoli, G. ; Caminati, M. ; Carpagnano, G.E. ; Caruso, C. ; Centanni, S. ; Conte, M.E. ; Corsico, A.G. ; Cosmi, L. ; Costantino, M.T. ; Crimi, N. ; D'Alò, S. ; D'Amato, M. ; Del Giacco, S. ; Farsi, A. ; Favero, E. ; Foschino Barbaro, M.P. ; Guarnieri, G. ; Guida, G. ; Latorre, M. ; Lo Cicero, S. ; Lombardi, C. ; Macchia, L. ; Mazza, F. ; Menzella, F. ; Milanese, M. ; Montagni, M. ; Montuschi, P. ; Nucera, E. ; Parente, R. ; Patella, V. ; Pelaia, G. ; Pini, L. ; Puggioni, F. ; Ricciardi, L. ; Ricciardolo, F.L.M. ; Richeldi, L. ; Ridolo, E. ; Rolla, G. ; Santus, P. ; Scichilone, N. ; Spadaro, G. ; Vianello, A. ; Viviano, V. ; Yacoub, M.R. ; Zappa, M.C. ; Heffler, E. ; Italy), SANI (Severe Asthma Network. / Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) : World Allergy Organization Journal. In: World Allergy Organ. J. 2020 ; Vol. 13, No. 10.

@article{222d91f8e8a74757a9a5810e379e3b5f,

title = "Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal",

abstract = "According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics. {\textcopyright} 2020 The Authors",

keywords = "Biologics, Oral corticosteroids, Real-life, Registr, Severe asthma, benralizumab, biological product, corticosteroid, dupilumab, mepolizumab, omalizumab, asthma, clinical outcome, disease exacerbation, disease registry, drug effect, forced expiratory volume, human, Italy, medication overuse, priority journal, quality of life, Review",

author = "G.W. Canonica and F. Blasi and P. Paggiaro and G. Senna and G. Passalacqua and A. Spanevello and S. Aliberti and D. Bagnasco and M. Bonavia and M. Bonini and L. Brussino and C. Bucca and M.F. Caiaffa and C. Calabrese and G. Camiciottoli and M. Caminati and G.E. Carpagnano and C. Caruso and S. Centanni and M.E. Conte and A.G. Corsico and L. Cosmi and M.T. Costantino and N. Crimi and S. D'Al{\`o} and M. D'Amato and {Del Giacco}, S. and A. Farsi and E. Favero and {Foschino Barbaro}, M.P. and G. Guarnieri and G. Guida and M. Latorre and {Lo Cicero}, S. and C. Lombardi and L. Macchia and F. Mazza and F. Menzella and M. Milanese and M. Montagni and P. Montuschi and E. Nucera and R. Parente and V. Patella and G. Pelaia and L. Pini and F. Puggioni and L. Ricciardi and F.L.M. Ricciardolo and L. Richeldi and E. Ridolo and G. Rolla and P. Santus and N. Scichilone and G. Spadaro and A. Vianello and V. Viviano and M.R. Yacoub and M.C. Zappa and E. Heffler and Italy), {SANI (Severe Asthma Network}",

note = "Cited By :1 Export Date: 11 March 2021 Correspondence Address: Heffler, E.; Personalized Medicine, Via Alessandro Manzoni 56, Italy; email: heffler.enrico@gmail.com Chemicals/CAS: benralizumab, 1044511-01-4; dupilumab, 1190264-60-8; mepolizumab, 196078-29-2; omalizumab, 242138-07-4 Funding details: AstraZeneca Funding text 1: SANI is supported through unrestricted grants by AstraZeneca, Glaxo Smith Kline, Novartis & Sanofi Genzyme.",

year = "2020",

doi = "10.1016/j.waojou.2020.100464",

language = "English",

volume = "13",

journal = "World Allergy Organ. J.",

issn = "1939-4551",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

T2 - World Allergy Organization Journal

AU - Canonica, G.W.

AU - Blasi, F.

AU - Paggiaro, P.

AU - Senna, G.

AU - Passalacqua, G.

AU - Spanevello, A.

AU - Aliberti, S.

AU - Bagnasco, D.

AU - Bonavia, M.

AU - Bonini, M.

AU - Brussino, L.

AU - Bucca, C.

AU - Caiaffa, M.F.

AU - Calabrese, C.

AU - Camiciottoli, G.

AU - Caminati, M.

AU - Carpagnano, G.E.

AU - Caruso, C.

AU - Centanni, S.

AU - Conte, M.E.

AU - Corsico, A.G.

AU - Cosmi, L.

AU - Costantino, M.T.

AU - Crimi, N.

AU - D'Alò, S.

AU - D'Amato, M.

AU - Del Giacco, S.

AU - Farsi, A.

AU - Favero, E.

AU - Foschino Barbaro, M.P.

AU - Guarnieri, G.

AU - Guida, G.

AU - Latorre, M.

AU - Lo Cicero, S.

AU - Lombardi, C.

AU - Macchia, L.

AU - Mazza, F.

AU - Menzella, F.

AU - Milanese, M.

AU - Montagni, M.

AU - Montuschi, P.

AU - Nucera, E.

AU - Parente, R.

AU - Patella, V.

AU - Pelaia, G.

AU - Pini, L.

AU - Puggioni, F.

AU - Ricciardi, L.

AU - Ricciardolo, F.L.M.

AU - Richeldi, L.

AU - Ridolo, E.

AU - Rolla, G.

AU - Santus, P.

AU - Scichilone, N.

AU - Spadaro, G.

AU - Vianello, A.

AU - Viviano, V.

AU - Yacoub, M.R.

AU - Zappa, M.C.

AU - Heffler, E.

AU - Italy), SANI (Severe Asthma Network

N1 - Cited By :1 Export Date: 11 March 2021 Correspondence Address: Heffler, E.; Personalized Medicine, Via Alessandro Manzoni 56, Italy; email: heffler.enrico@gmail.com Chemicals/CAS: benralizumab, 1044511-01-4; dupilumab, 1190264-60-8; mepolizumab, 196078-29-2; omalizumab, 242138-07-4 Funding details: AstraZeneca Funding text 1: SANI is supported through unrestricted grants by AstraZeneca, Glaxo Smith Kline, Novartis & Sanofi Genzyme.

PY - 2020

Y1 - 2020

N2 - According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics. © 2020 The Authors

AB - According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics. © 2020 The Authors

KW - Biologics

KW - Oral corticosteroids

KW - Real-life

KW - Registr

KW - Severe asthma

KW - benralizumab

KW - biological product

KW - corticosteroid

KW - dupilumab

KW - mepolizumab

KW - omalizumab

KW - asthma

KW - clinical outcome

KW - disease exacerbation

KW - disease registry

KW - drug effect

KW - forced expiratory volume

KW - human

KW - Italy

KW - medication overuse

KW - priority journal

KW - quality of life

KW - Review

U2 - 10.1016/j.waojou.2020.100464

DO - 10.1016/j.waojou.2020.100464

M3 - Article

VL - 13

JO - World Allergy Organ. J.

JF - World Allergy Organ. J.

SN - 1939-4551

IS - 10

ER -

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal

Abstract

Keywords

Access to Document

Fingerprint

Cite this